A Phase 1, Randomized, Open-label, Single-dose, Two-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of the Pre-filled Syringe and Auto-injector of CT-P13 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Celltrion
- 16 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2018 New trial record